Quantcast

Latest Trastuzumab Stories

2011-12-08 12:55:30

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant.

2011-12-08 12:53:09

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo.

2011-12-07 14:36:01

One study presented at the meeting, which is being held in Budapest, Hungary, 7 to 10 December, reports on an initiative using echocardiography to document early warning signs of adverse effects from trastuzumab (Herceptin ®)¹, while the other uses echocardiography to evaluate the protective role of ACE inhibitors and statins on the hearts of cancer patients².

2011-12-01 19:03:26

Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin® (trastuzumab).

2011-11-04 12:00:00

Current testing protocols for HER2 amplification may exclude thousands of patients who actually have HER2 gene amplification, delaying or preventing them from receiving potentially life-saving


Word of the Day
logocentrism
  • The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.
The word 'logocentrism' is a blend of logo- +‎ centrism.
Related